Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Perioperative Vitamin C Lung Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04505878
Recruitment Status : Not yet recruiting
First Posted : August 10, 2020
Last Update Posted : December 9, 2020
Sponsor:
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:
This study is being done to determine if parenterally administered ascorbic acid (Vitamin C) given at the time of lung transplant is safe. Vitamin C may be an effective intervention towards primary graft dysfunction (PGD). The study will enroll 69 participants who consent to the intervention. Participants who do not consent to the intervention will be treated according to standard-of-care, but may choose to be consented to have their data retrospectively reviewed. Based on our consent rate, this group may include 40-70 participants. Participants will be on study for up to 12 months.

Condition or disease Intervention/treatment Phase
Primary Graft Dysfunction Lung Transplant; Complications Drug: Vitamin C Phase 2

Detailed Description:

PGD is a frequent and severe outcome that impacts both short- and long-term outcomes after lung transplantation. Major pathophysiologic contributors include ischemia and reperfusion injury, mitochondrial dysfunction and endothelial failure. No directed therapy exists. Vitamin C is a first-line antioxidant that also acts at the endothelium and mitochondria to decrease permeability and leak, inhibit mitochondrial dysfunction and improve ischemia and reperfusion. When combined with steroids, part of standard care for lung transplant recipients, these effects may be enhanced and synergistically inhibit instigators of patient injury. A pilot trial will ensure safety of this potential intervention and guide future research into this important outcome measure. It will be readily received in the literature.

For the present study, vitamin C will be administered parenterally at a dose of 1,500 mg every 6 hours, a dose that is widely accepted and used in other clinical contexts where the drug is studied, such as sepsis. This will predictably reconstitute levels and achieve supratherapeutic benefit towards oxidant scavenging, while avoiding the potential pro-oxidant effects seen at exceedingly high doses. To this end, the investigators will exclude patients where the standard dosing of vitamin C will exceed 100 mg/kg/day (excluding patients <60 kg). Dosing will continue through post-operative day (POD) 3 to effectively assess for the impact of vitamin C on PGD.

Primary Objectives

  • To assess whether parenterally administered ascorbic acid (vitamin C) is safe in the lung transplant population
  • To estimate adherence to ascorbic acid administration protocol in this study population and to identify obstacles to feasibility of future trials using this protocol

Secondary Objectives

  • To assess whether parenterally administered ascorbic acid (vitamin C) may decrease the rate and severity of PGD after lung transplant
  • To establish the incidence of vitamin C and vitamin B1 (thiamine) deficiencies in the lung transplant population, and the responsiveness of vitamin C levels to our selected parenteral therapy
  • To identify interventions that will optimize the post-operative wellbeing of patients receiving lung transplants by decreasing primary graft dysfunction (short and intermediate-to-long term

Stop Criteria

  • Anuria x 3-hours
  • Moderate, Grade 2 AKI (doubling of baseline creatinine)
  • An acute, unexplained hemoglobin drop of >2 mg/dL

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 110 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This is a pilot single-arm unblinded trial to assess whether parenterally administered ascorbic acid (vitamin C) is safe in the lung transplant population.The investigators will not randomize or control; a retrospective cohort of participants not treated with vitamin C will be reviewed from 2015-2020. Those participants who decline the intervention will have the choice to consent to having their data be considered as part of the (non-retrospective) controls and be considered in our statistical analysis for outcomes, including analysis between this group and the historical controls. All participants who consent will be administered the therapy and participants will be evaluated via an intention-to-treat analysis.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Vitamin C: Assessing Safety After Lung Transplant
Estimated Study Start Date : April 2021
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Vitamin C Arm
Ascorbic Acid will be administered at a dose of 1500 mg in 100 mL of saline over 30 minutes intravenously once every 6 hours for a total of 72 hours
Drug: Vitamin C
Vitamin C is a first-line antioxidant that directly scavenges free radicals, inhibits reactive oxygen species (ROS) producing enzymes and recovers other cellular antioxidants
Other Name: ascorbic acid




Primary Outcome Measures :
  1. Incidence and Severity of Kidney Injury Post Operative Day (POD) 1 [ Time Frame: Post Operative Day 1 ]
    The primary endpoint is the safety of the vitamin C intervention. This will be measured by the incidence and severity of kidney injuries on POD 1, POD 2, POD 3, POD 4, and POD 7. Acute kidney injury (AKI) is defined as any creatinine (Cr) that is 1.5-times the participant's baseline / immediate preoperative creatinine. Severity escalates with increasing ratios: Mild, stage 1 AKI (Cr 1.5-1.99x baseline); Moderate, stage 2 AKI (Cr 2-2.9x baseline); and Severe, stage 3 AKI (Cr >3x baseline or any initiation of dialysis).

  2. Incidence and Severity of Kidney Injury POD 2 [ Time Frame: Post Operative Day 2 ]
    The primary endpoint is the safety of the vitamin C intervention. This will be measured by the incidence and severity of kidney injuries on POD 1, POD 2, POD 3, POD 4, and POD 7. Acute kidney injury (AKI) is defined as any creatinine (Cr) that is 1.5-times the participant's baseline / immediate preoperative creatinine. Severity escalates with increasing ratios: Mild, stage 1 AKI (Cr 1.5-1.99x baseline); Moderate, stage 2 AKI (Cr 2-2.9x baseline); and Severe, stage 3 AKI (Cr >3x baseline or any initiation of dialysis).

  3. Incidence and Severity of Kidney Injury POD 3 [ Time Frame: Post Operative Day 3 ]
    The primary endpoint is the safety of the vitamin C intervention. This will be measured by the incidence and severity of kidney injuries on POD 1, POD 2, POD 3, POD 4, and POD 7. Acute kidney injury (AKI) is defined as any creatinine (Cr) that is 1.5-times the participant's baseline / immediate preoperative creatinine. Severity escalates with increasing ratios: Mild, stage 1 AKI (Cr 1.5-1.99x baseline); Moderate, stage 2 AKI (Cr 2-2.9x baseline); and Severe, stage 3 AKI (Cr >3x baseline or any initiation of dialysis).

  4. Incidence and Severity of Kidney Injury POD 4 [ Time Frame: Post Operative Day 4 ]
    The primary endpoint is the safety of the vitamin C intervention. This will be measured by the incidence and severity of kidney injuries on POD 1, POD 2, POD 3, POD 4, and POD 7. Acute kidney injury (AKI) is defined as any creatinine (Cr) that is 1.5-times the participant's baseline / immediate preoperative creatinine. Severity escalates with increasing ratios: Mild, stage 1 AKI (Cr 1.5-1.99x baseline); Moderate, stage 2 AKI (Cr 2-2.9x baseline); and Severe, stage 3 AKI (Cr >3x baseline or any initiation of dialysis).

  5. Incidence and Severity of Kidney Injury POD 7 [ Time Frame: Post Operative Day 7 ]
    The primary endpoint is the safety of the vitamin C intervention. This will be measured by the incidence and severity of kidney injuries on POD 1, POD 2, POD 3, POD 4, and POD 7. Acute kidney injury (AKI) is defined as any creatinine (Cr) that is 1.5-times the participant's baseline / immediate preoperative creatinine. Severity escalates with increasing ratios: Mild, stage 1 AKI (Cr 1.5-1.99x baseline); Moderate, stage 2 AKI (Cr 2-2.9x baseline); and Severe, stage 3 AKI (Cr >3x baseline or any initiation of dialysis).

  6. Incidence of New Dialysis Initiation [ Time Frame: up to Post Operative Day 7 ]

Secondary Outcome Measures :
  1. Participant Vitamin C Levels [ Time Frame: Baseline, Post Operative Day 1, Post Operative Day 2, Post Operative Day 3 ]
  2. Participant Thiamine Levels [ Time Frame: Baseline, Post Operative Day 1, Post Operative Day 2, Post Operative Day 3 ]
  3. Incidence of Primary Graft Dysfunction (PGD) [ Time Frame: up to Post Operative Day 7 ]
    Primary Graft Dysfunction is defined as chest x-ray (CXR)-infiltrates with or without depressed oxygenation function, assessed by the "PF-Ratio," which is the PaO2 / FiO2.

  4. Incidence and Severity of PGD on POD 3 [ Time Frame: Post Operative Day 3 ]
    Primary Graft Dysfunction is defined as chest x-ray (CXR)-infiltrates with or without depressed oxygenation function, assessed by the "PF-Ratio," which is the PaO2 / FiO2. Severity is defined as: PGD Grade 1 = CXR findings and any PF Ratio > 300; PGD Grade 2 = CXR findings and PF Ratio 200-300; and PGD Grade 3 = CXR findings and PF Ratio <200.

  5. Tacrolimus Levels [ Time Frame: Post Operative Days 2, 3, 4, and 7 ]
  6. Tacrolimus Doses [ Time Frame: Post Operative Days 4 and 7 ]
  7. Post-Operative Well Being: Mortality [ Time Frame: at Post Operative Day 30 and Post Operative Day 90 via chart review ]
  8. Post-Operative Well Being: Atrial Fibrillation [ Time Frame: up to Post Operative Day 7 ]
  9. Post-Operative Well Being: ICU Length of Stay [ Time Frame: up to Post Operative Day 30 (chart review) ]
  10. Post-Operative Well Being: Hospital Length of Stay [ Time Frame: up to Post Operative Day 90 (chart review) ]
  11. Post-Operative Well Being: Nadir Cardiac Index [ Time Frame: up to 72 hours post op ]
  12. Post-Operative Well Being: Peak Pulmonary Artery Systolic Pressure [ Time Frame: up to 72 hours post op ]
  13. Post-Operative Well Being: Peak Pulmonary Artery Diastolic Pressure [ Time Frame: up to 72 hours post op ]
  14. Post-Operative Well Being: Duration of Inotrope Need [ Time Frame: up to 72 hours post op ]
  15. Post-Operative Well Being: Duration of Vasopressor [ Time Frame: up to 72 hours post op ]
  16. Post-Operative Well Being: Total Dose of Vasopressor [ Time Frame: up to 72 hours post op ]
  17. Post-Operative Well Being: Daily Crystalloid Volume [ Time Frame: up to 72 hours post op ]
    for 0-24h, 24-48h and 48-72h; total volume balance at 72-hours

  18. Post-Operative Well Being: Daily Blood Product Transfusion Volume [ Time Frame: up to 72 hours post op ]
    for 0-24h, 24-48h and 48-72h; total volume balance at 72-hours

  19. Post-Operative Well Being: Daily Chest Tube Output Volume [ Time Frame: up to 72 hours post op ]
    for 0-24h, 24-48h and 48-72h; total volume balance at 72-hours

  20. Post-Operative Well Being: Duration of Post-Operative Mechanical Ventilation [ Time Frame: up to Post Operative Day 7 ]
  21. Post-Operative Well Being: PaO2 / FIO2 ratios [ Time Frame: Post Operative Day 1, Post Operative Day 2, Post Operative Day 3 ]
    The PF Ratio assesses the lungs' ability to oxygenate the blood. It is defined as the ratio of the partial pressure of oxygen in the arteries (PaO2 in mmHg) to the fractional inspired oxygen content from the ventilator (FiO2 in %).

  22. Post-Operative Well Being: Time to Clearance of Lactate [ Time Frame: up to Post Operative Day 3 ]
    "Clearance" is defined as a lactate <1 mmol/L.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participant is scheduled for lung transplantation

Exclusion Criteria:

  • History of nephrolithiasis, oxalosis or oxaluria
  • History of sickle cell anemia, glucose-6-phosphate dehydrogenase deficiency or hereditary hemochromatosis
  • Weight <60 kg
  • Participant taking vitamin C supplements or those who have received Hydrocortisone, ascorbic acid, and thiamine (HAT) therapy in the 1-month prior to transplantation
  • Baseline creatinine >2 mg/dL or any current kidney injury

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04505878


Contacts
Layout table for location contacts
Contact: Helen F Akere (608) 265-3243 akere@wisc.edu

Locations
Layout table for location information
United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792
Contact: Helen Akere    608-265-3243    akere@wisc.edu   
Sponsors and Collaborators
University of Wisconsin, Madison
Investigators
Layout table for investigator information
Principal Investigator: Micah Long, MD UW School of Medicine and Public Health
Layout table for additonal information
Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT04505878    
Other Study ID Numbers: 2020-0503
A530900 ( Other Identifier: UW Madison )
SMPH/ANESTHESIOLOGY ( Other Identifier: UW Madison )
Protocol Version 6/26/2020 ( Other Identifier: UW Madison )
First Posted: August 10, 2020    Key Record Dates
Last Update Posted: December 9, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data from this study may be requested from other researchers up to 7 years after the completion of the primary endpoint by contacting Dr. Micah Long, the Principal Investigator of this study.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: up to 7 years after the completion of the primary endpoint

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Wisconsin, Madison:
Vitamin C
Additional relevant MeSH terms:
Layout table for MeSH terms
Primary Graft Dysfunction
Reperfusion Injury
Vascular Diseases
Cardiovascular Diseases
Postoperative Complications
Pathologic Processes
Ascorbic Acid
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents